Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Total Current Liabilities (2016 - 2025)

Cardiff Oncology's Total Current Liabilities history spans 15 years, with the latest figure at $16.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 22.09% year-over-year to $16.4 million; the TTM value through Dec 2025 reached $16.4 million, up 22.09%, while the annual FY2025 figure was $16.4 million, 22.09% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $16.4 million at Cardiff Oncology, up from $14.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $16.7 million in Q2 2025 and bottomed at $4.5 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $8.5 million (2022), against an average of $10.1 million.
  • The largest annual shift saw Total Current Liabilities decreased 8.24% in 2021 before it skyrocketed 85.22% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $6.6 million in 2021, then grew by 19.04% to $7.8 million in 2022, then soared by 33.71% to $10.4 million in 2023, then rose by 28.62% to $13.4 million in 2024, then rose by 22.09% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Total Current Liabilities are $16.4 million (Q4 2025), $14.7 million (Q3 2025), and $16.7 million (Q2 2025).